Share
))
HBO and The Ringer's Bill Simmons hosts the most downloaded sports podcast of all time, with a rotating crew of celebrities, athletes, and media staples, as well as mainstays like Cousin Sal, Joe House, and a slew of other friends and family members who always happen to be suspiciously available.
…
continue reading
Manage episode 519951998 series 3672166
Content provided by Kavout. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Kavout or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
This episode report on the major acquisition of Halda Therapeutics by Johnson & Johnson (J&J) for $3.05 billion in cash, a move intended to significantly enhance J&J's oncology pipeline, particularly in prostate cancer treatments. Central to the deal is Halda’s proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC) platform and its lead candidate, HLD-0915, an oral therapy demonstrating promising early efficacy in treating metastatic castration-resistant prostate cancer (mCRPC). The sources highlight that this acquisition, which also includes earlier-stage candidates for breast and lung cancers, supports J&J's broader goal of reaching $50 billion in cancer sales by 2030. Expected to close within the next few months, the transaction is recognized as an important strategic investment, although J&J anticipates a slight dilution to its 2026 adjusted earnings per share due to closing-related charges.
Disclaimer: This podcast by kavout.com is for informational and educational purposes only and does not constitute investment advice. All opinions are those of the hosts and guests. Please consult a qualified financial advisor before making any investment decisions.
135 episodes
